Inhibitors of aurora kinases;Les inhibiteurs des kinases Aurora

Annales Pharmaceutiques Francaises

Volumn 67, Issue 2, 2009, Pages 69-77

  Pinel, S ^a   Barbault Foucher, S ^a   Lott Desroches, M C ^a   Astier, A ^b  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

Aurora kinases; Cell division; Inhibitors of aurora kinases; Tumor

Indexed keywords

2 [[3 [4 [5 [2 (3 FLUOROANILINO) 2 OXOETHYL] 1H PYRAZOL 3 YLAMINO] 7 QUINAZOLINYLOXY]PROPYL](ETHYL)AMINO]ETHYL DIHYDROGEN PHOSPHATE; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; ANTINEOPLASTIC AGENT; AT 9283; AURORA A KINASE; AURORA B KINASE; AURORA C KINASE; AURORA KINASE INHIBITOR; BIOLOGICAL MARKER; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DEXAMETHASONE; DOCETAXEL; ENDOSTATIN; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; IRINOTECAN; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; NAVELBINE; OXALIPLATIN; PHA 680632; PHA 739358; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN CITRATE; UNCLASSIFIED DRUG; VINCRISTINE SULFATE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER CANCER; BREAST CANCER; CARBOXY TERMINAL SEQUENCE; CENTROSOME; CHROMOSOME CONDENSATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CYTOKINESIS; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; ENZYME STRUCTURE; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MITOSIS; NONHUMAN; PANCREAS CANCER; PROGNOSIS; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE; SHORT SURVEY; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES;

EID: 68949171956     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2008.12.005     Document Type: Short Survey

References (56)

1. Warner S.L., Bearss D.J., Han H., and Von Off D.D. Targeting Aurora-2 kinase in cancer. Mol Cancer Ther 2 (2003) 589-595
2. Lavelle F. L'inhibiteur de kinases Aurora VX680, chef de file d'une nouvelle famille d'agents antitumoraux. Bull cancer 91 (2004) 330-331
3. Mountzios G., Terpes E., and Dimopoulos M.A. Kinases Aurora as targets for cancer therapy. Cancer Treat Rev 34 (2008) 175-182
4. Carmena M., and Earnshaw W.C. The cellular geography of kinases Aurora. Nat Rev Mol Cell Biol 4 (2003) 842-854
5. Bolanos-Garcia V.M. Kinases Aurora. Int J Biochem Cell B 37 (2005) 1572-1577
6. Tari L.W., Hoffman I.D., Bensen D.C., Hunter M.J., Nix J., Nelson K.J., et al. Structural basis for the inhibition of Aurora A kinase by a novel class of high affinity disubstituted pyrimidine inhibitors. Bioorg Med Chem Lett 17 (2007) 688-691
7. Meijer L. Le cycle de division cellulaire et sa régulation. Bull Cancer 2006;41-53 [hors série]
8. er avril 2008, mise en ligne : décembre 2000, dernière modification : 17 janvier 2002.
9. Kollaredy M., Dzubak P., Zheleva D., and Hadjduch M. Aurora kinases: structure, functions and their association with cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 152 (2008) 27-33
10. Castro A., Arlot-Bonnemains Y., Vigneron S., Labbe J.C., Prigent C., and Lorca T. APC/Fizzy-Related targets Aurora-A kinase for proteolysis. EMBO Rep 3 (2002) 457-462
11. Sessa F., Mapelli M., Ciferri C., Tarricone C., and Areces L.B. Mechanism of Aurora B activation by INCENP and inhibition by hesperadin. Mol Cell 18 (2005) 379-391
12. Andrews P.D., Knatko E., Moore W.J., and Swedlow J.R. Mitotic mechanics: the Auroras into view. Curr Opin Cell Biol 15 (2003) 672-683
13. Kimura M., Matsuda Y., Yoshioka T., Sumi N., and Okano Y. Identification and characterization of STK12/Aik2: a human gene related to Aurora of Drosphila and yeast IPL1. Cytogenet Cell Genet 82 (1998) 147-152
14. Ikezoe T. Kinases Aurora as an anticancer target. Cancer Lett 262 (2008) 1-9
15. Tseng T.C., Chen S.H., Hsu Y., and Tang T.K. Protein kinase profile of sperm and eggs: cloning and characterization of two novels testis specific protein kinases (AIE1, AEI2) related to yeast and fly chromosome segregation regulators. DNA Cell Biol 17 (1998) 823-833
16. Montembault E, Prigent C. Kinases Aurora: therapeutic potential. Drugs of the future. 2005:30. http://mandrake.med.univ-rennes1.fr/Intranet/projet_labo/publi_pdf/AUROR A %20 KINASES:%20THERAPEUTIC %20POTENTIAL.pdf consulté le 16 avril 2008.
17. Sun C., Chan F., Briassouli P., and Linardopoulos S. Aurora kinase inhibition downregulates NFKB and sensitises tumour cells to chemotherapeutic agents. Biochem Bioph Res Co 352 (2007) 220-225
18. Sen S., Zhou H., and White R.A. A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene 14 (1997) 2195-2200
19. Katayama H., Brinkley W.R., and Sen S. The kinases Aurora: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 22 (2003) 451-464
20. Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F., et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 36 (2004) 55-62
21. Liu Q., Kaneko S., Yang L., Feldman R.I., Nicosia S.V., Chen J., et al. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem 279 (2004) 52175-52182
22. Jeng M.Y., Peng S.Y., Lin C.Y., and Hsu H.C. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 10 (2004) 2065-2071
23. Anand S., Penrhyn-Lowe S., and Venkitaraman A.R. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 3 (2003) 51-62
24. Ota T., Suto S., Katayama H., Han Z.B., Suzuki F., Maeda M., et al. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res 62 (2002) 5168-5177
25. Tatsuka M., Katayama H., Ota T., Taraka T., Odashima S., Suzuki F., et al. Multinuclearity and increased ploidy caused by overexpression of the Aurora and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. Cancer Res 58 (1998) 4811-4816
26. http://www.crimsoncanary.com/Documents/Aurora_Kinase.pdf Consulté le 16 avril 2008.
27. http://www.pnas.org/content/104/10/4106/suppl/DC1 Consulté le 12 novembre 2008.
28. Talele T., and McLaughlin M. Molecular docking/dynamics studies of Aurora A kinase inhibitors. J Mol Graph Model 26 (2008) 1213-1222
29. Harrington E.A., Bebbington D., Moore J., Rasmussen R.K., Ajose-Adeogun A.Q., Nakayama T., et al. VX-680, a potent and selective small-molecule inhibitor of the Kinases Aurora suppresses tumor growth in vivo. Nat Med 10 (2004) 262-267
30. Rubin E.H., Shapiro G.I., and Stein MN. A phase I clinical and pharmacokinetic trial of the Aurora kinase inhibitor MK-0457 in cancer patients. J Clin Oncol 24 (2006) abstract 3008 18S
31. Gautshi O., Heighway J., Mack P.C., Purnell P.R., Lara P.N., and Gandara D.R. Aurora kinases as anticancer drug targets. Clin Cancer Res 14 (2008) 1639-1648
32. Giles F.J., Cortes J., Jones D., Bergstrom D., Kantarjian H., and Freedman S.J. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109 (2007) 500-502
33. Cheetman G.M.T., Charlton P.A., Golec J.M.C., and Pollard J.R. Structural basis for potent inhibition of the kinases Aurora and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett 251 (2007) 323-329
34. Lin Y.G., Immanemi A., Merritt W.M., Mangala L.S., Kim S.W., Shahzad M.M., et al. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res. 14 (2008) 5437-5446
35. Marumoto T., Honda S., Hara T., Nitta M., Hirota T., Kohmura E., et al. Aurora -a kinase maintains the fidelity of early and late mitotic events in Hela cells. J Biol. Chem. 278 (2003) 51786-51795
36. Hoar K., Chakravarty A., Rabino C., Wysong D., Bowman D., Roy N., et al. MLN8054, a small-molecule inhibitor of Aurora-A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol 12 (2007) 4513-4525
37. LeRoy P.J., Hunter J.J., Hoar K.M., Burke K.E., Shinde V., Ruan J., et al. Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A: a novel pharmacodynamic method for measuring Aurora A activity. Cancer Res 67 (2007) 5362-5370
38. Manfredi M.G., Ecsedy J.A., Meetze K.A., Burenkova S.K., Chen W., Galvin K.M., et al. Antitumor activity of MLN8054, an orally small-molecule Aurora A kinase. Proc Natl Acad Sci USA 104 (2007) 4106-4111
39. Mortlock A.A., Foote K.M., Heron N.M., Jung F.H., Pasquet G., Lohmann, et al. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of Aurora B kinase. J Med Chem 50 (2007) 2213-2224
40. Walsby E., Walsh V., Pepper C., Burnett A., and Mills K. Effects of the Aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukaemia cell lines and primary blasts. Haematologica 93 (2008) 662-669
41. Tao Y., Zhang P., Girdler F., Frascogna V., Castedo M., Bourhis J., et al. Enhancement of radiation response in p-53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152. Oncogene 27 (2008) 3244-3255
42. Evans R.P., Naber C., Steffler T., Checkland T., Maxwell C.A., Keats J.J., et al. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haemotol 140 (2008) 295-302
43. Yang J., Ikezoe T., Nishioka C., Tasaka T., Taniguchi A., Kuwayama Y., et al. AZD1152, a novel and selective Aurora B kinase inhibitor, induces growh arrest, apoptosis, and sensibilization for tubulin depolymerising agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 110 (2007) 2034-2040
44. Schellens J.H., Boss D., Witteveen P.O., Zandvliet A., and Beijnen J.H. Phase 1 and pharmacological study of the novel Aurora kinase inhibitor AZD1152. J Clin Oncol 24 (2006) (122s)
45. Modugno M., Casale E., Soncini C., Rosettani P., Colombo R., Lupi R., et al. Crystal structure of the T315I Abl mutant in complex with the kinases Aurora inhibitor PHA-739358. Cancer Res 67 (2007) 7987-7990
46. Gontarewicz A., Balabano S., Keller G., Colombo R., Graziano A., Pesenti D., et al. Simultaneous targeting of kinases Aurora and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 111 (2008) 4355-4364
47. Timke C., Zieher H., Roth A., Hauser K., Lipson K.E., Weber K.J., et al. Combination of vascular endothelial growth factor receptor: platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res 14 (2008) 2210-2219
48. http://www.nci.nih.gov/Templates/drugdictionary.aspx?CdrID=489092 Consulté le 12 novembre 2008.
49. Klenke F.M., Abdollahi A., Bertl E., Gebhard M.M., Ewerbeck V., Huber P.E., et al. Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo. BMC Cancer 7 (2007) 49
50. Godl K., Gruss O.J., Eickhoff J., Wissing J., Blencke S., Weber M., et al. Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signalling. Cancer Res 65 (2005) 6919-6926
51. Giavazzi R., Bani M.R., and Taraboletti G. Tumor-host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds. Cancer Metastasis Rev 26 (2007) 481-488
52. Faccioli N., Marzola P., Boschi F., D'Onofrio M., and Pozzi Mucelli R. Pathological animal models in the experimental evaluation of tumour microvasculature with magnetic resonance imaging. Radiol Med 112 (2007) 319-328
53. Zeng Q.L., Chu Z.H., Zhou K., and Luo X.J. Effect of endostatine and SU6668 combined with 5-FU on human colon cancer xenograft in nude mice. Zonghua Wei Chang Wai Ke Za Zhi 11 (2008) 376-378
54. Foran J.M., Ravandi F., O'Brien S.M., Borthakur G., Rios M., et al. Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor refractory leukaemia. Journal of clinical oncology 26 (2008) 2008-2518
55. Ikezoe T., Yang J., Nishioka C., Tasaka T., Tanigucchi A., Kuwayama Y., et al. À novel treatment strategy targeting kinases Aurora in acute myelogenous leukemia. Mol Cancer Ther 6 (2007) 1851-1857
56. Gadea B.B., and Ruderman J.V. Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the etablishment of the spindle integrity checkpoint in xenopus egg extracts. Mol Cell Biomech 10 (2004) 1091